Biological and steroid use in relationship to quality measures in older patients with inflammatory bowel disease: A US Medicare cohort study

BMJ Open

Volumn 5, Issue 9, 2015, Pages

  Johnson, Sophia L ^a   Bartels, Christie M ^b   Palta, Mari ^b   Thorpe, Carolyn T ^c,d   Weiss, Jennifer M ^b   Smith, Maureen A ^b  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^d UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; INFLIXIMAB; STEROID; MONOCLONAL ANTIBODY; TNF PROTEIN, HUMAN; TUMOR NECROSIS FACTOR;

AGE; AGED; ARTICLE; COHORT ANALYSIS; DRUG UTILIZATION; FEMALE; HEALTH CARE QUALITY; HOSPITALIZATION; HUMAN; INCIDENCE; INFLAMMATORY BOWEL DISEASE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MEDICAID; MEDICARE; PRACTICE GUIDELINE; PREVALENCE; RETROSPECTIVE STUDY; ECONOMICS; IMMUNOLOGY; INFLAMMATORY BOWEL DISEASES; MULTIVARIATE ANALYSIS; REGRESSION ANALYSIS; RISK FACTOR; UNITED STATES; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; INFLIXIMAB; MALE; MEDICARE; MULTIVARIATE ANALYSIS; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; RISK FACTORS; STEROIDS; TUMOR NECROSIS FACTOR-ALPHA; UNITED STATES;

EID: 84947708271     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2015-008597     Document Type: Article

References (46)

1. Park K, Bass D. Inflammatory bowel disease-Attributable costs, and cost-effective strategies in the United States: a review. Inflamm Bowel Dis 2011; 17: 1603-9
2. Kappelman M, Rifas-Shiman S, Porter C, et al. Direct health care costs of Crohn?s disease, and ulcerative colitis in US children, and adults. Gastroenterology 2008; 135: 1907-13
3. Feagan B, Lemann M, Befrits R, et al. Recommendations for the treatment of Crohn?s disease with tumor necrosis factor antagonists: an expert consensus report. Inflamm Bowel Dis 2012; 18: 152-60
4. Sherman M, Tsynman D, Kim A, et al. Sustained improvement in health-related quality of life measures in patients with inflammatory bowel disease receiving prolonged anti-Tumor necrosis factor therapy. J Dig Dis 2014; 15: 174-9
5. van Assche G, Vermeire S, Rutgeerts P. Mucosal healing, and anti TNFs in IBD. Curr Drug Targets 2010; 11: 227-33
6. Allen P, Peyrin-Biroulet L. Moving towards disease modification in inflammatory bowel disease therapy. Curr Opin Gastroenterol 2013; 29: 397-404
7. Curkovic I, Egbring M, Kullak-Ublick G. Risks of inflammatory bowel disease treatment with glucocorticosteroids, and aminosalicylates. Dig Dis 2013; 31: 368-73
8. Lichtenstein GR, Yan S, Bala M, et al. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn?s disease. Gastroenterology 2005; 128: 862-9
9. Rubenstein J, Chong R, Cohen R. Infliximab decreases resource use among patients with Crohn?s disease. J Clin Gastroenterol 2002; 35: 151-6
10. Foote SB, Halaas GW. Defining a future for fee-for-service Medicare. Health Aff 2006; 25: 864-8
11. Szrek S, Bundorf MK. Enrollment in prescription drug insurance: the interaction of numeracy, and choice set size. Health Psychol 2014; 33: 340-8
12. Centers for Medicaid, and Medicare Services. Dual eligible beneficiaries under the Medicare, and Medicaid Programs. 2014. http://www.cms.gov/Outreach-And-Education/Medicare-Learning-Network-MLN/MLNProducts/downloads/Medicare-Beneficiaries-Dual-Eligibles-At-a-Glance.pdf (accessed 23 Jul 2015
13. Centers for Medicare, and Medicaid Services. 2011 Physician Quality Reporting System, 2011. http://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/PQRS/2011-Physician-Quality-Reporting-System.html (accessed 4 Apr 2013
14. Cottone M, Kohn A, Daperno M, et al. Advanced age is an independent risk factor for severe infections, and mortality in patients given anti-Tumor necrosis factor therapy for inflammatory bowel disease. Clin Gastroenterol Hepatol 2011; 9: 30-5
15. Juneja M, Baidoo L, Schwartz M, et al. Geriatric inflammatory bowel disease: phenotypic presentation, treatment patterns, nutritional status, outcomes, and comorbidity. Dig Dis Sci 2012; 57: 2408-15
16. Ha C, Ullman T, Siegel C, et al. Patients enrolled in randomized controlled trials do not represent the inflammatory bowel disease patient population. Clin Gastroenterol Hepatol 2012; 10: 1002-7
17. Katz S, Pardi D. Inflammatory bowel disease of the elderly: frequently asked questions (FAQs). Am J Gastroenterol 2011; 106: 1889-97
18. Pardi D, Loftus E, Camilleri M. Treatment of inflammatory bowel disease in the elderly. Drugs Aging 2002; 19: 355-63
19. Picco M, Cangemi J. Inflammatory bowel disease in the elderly. Gastroenterol Clin N Am 2009; 38: 447-62
20. Liu L, Allison J, Herrinton L. Validity of computerized diagnoses, procedures, and drugs for inflammatory bowel disease in northern California managed care organization. Pharmacoepidemiol Drug Saf 2009; 18: 1086-93
21. Joynt K, Orav E, Jha A. The association between hospital volume, and processes, outcomes, and costs of care for congestive heart failure. Ann Intern Med 2011; 154: 94-102
22. D?Haens G, Panaccione R, Higgins P, et al. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn?s, and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?. Am J Gastroenterol 2011; 106: 199-212
23. MEDPac. Report to the Congress: Medicare, and the Health Care Delivery System. 2012. http://www.medpac.gov/chapters/Jun12-Ch06-APPENDIX.pdf (accessed 4 Apr 2013
24. Centers for Medicare, and Medicaid Services. Medicare claims processing manual, chapter 17: drugs, and biologicals. Baltimore, MD: Centers for Medicare & Medicaid Services, 2012
25. Bryson C, Au D, Young B, et al. A refill adherence algorithm for multiple short intervals to estimate refill compliance (ReComp). Med Care 2007; 45: 497-504
26. Curtis J, Westfall A, Allison J, et al. Longitudinal patterns in the prevention of osteoporosis in glucocorticoid-Treated patients. Arthritis Rheum 2005; 52: 2485-94
27. Feldstein AC, Elmer PJ, Nichols GA, et al. Practice patterns in patients at risk for glucocorticoid-induced osteoporosis. Osteoporosis Int 2005; 16: 2168-74
28. Bewtra M, Su C, Lewis J. Trends in hospitalization rates for inflammatory bowel disease in the United States. Clin Gastroenterol Hepatol 2007; 5: 597-601
29. Herrinton L, Liu L, Weng X, et al. Role of thiopurine, and anti-TNF therapy in lymphoma in inflammatory bowel disease. Am J Gastroenterol 2011; 106: 2146-53
30. Cairns S, Scholefield J, Steele R, et al. Guidelines for colorectal cancer screening, and surveillance in moderate, and high risk groups (update from 2002). Gut 2010; 59: 666-90
31. Fincke B, Snyder K, Cantillon C, et al. Three complementary definitions of polypharmacy: methods, application, and comparison of findings in a large prescription database. Pharmacoepidemiol Drug Saf 2005; 14: 121-8
32. Charlson M, Pompei P, Ales K, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development, and validation. J Chronic Dis 1987; 40: 373-83
33. American Gastroenterological Association Institute. IBD CPT codes ulcerative colitis & Crohn?s disease. Association TAG. http://www.gastro. org/practice/clinical-service-line/525-325PNQ-13-2-PDF-Document-Updates-CPT-Codes-IBD-Final.pdf (accessed 11 Apr 2014
34. USDA Economic Research Service. Rural Urban Commuting Area Codes. 2005. http://www.ers.usda.gov/data-products/rural-urbancommuting-Area-codes.aspx (accessed 4 Apr 2013
35. vanDeen W, vanOijen M, Myers K, et al. A nationwide 2010-2012 analysis of U.S. health care utilizaiton in inflammatory bowel diseases. Inflamm Bowel Dis 2014; 20: 1747-53
36. Targownik L, Bernstein C. Infectious, and malignant complications of TNF inhibitor therapy in IBD. Am J Gastroenterol 2013; 108: 1835-42
37. Zhang J, Xie F, Delzell E, et al. Association between vaccination for herpes zoster, and risk of herpes zoster infection among older patients with selected immune-mediated diseases. J Am Med Assoc 2012; 308: 43-9
38. Yazdany J, Tonner C, Schmajuk G. Use, and spending on biologic disease-modifying anti-rheumatic drugs for rheumatoid arthritis among US Medicare Beneficiaries. Arth Care Res 2015; 67: 1210-8
39. Zhang J, Xie F, Delzell E, et al. Trends in the use of biologic agents among rheumatoid arthritis patients enrolled in the US Medicare program. Arthritis Care Res 2013; 65: 1743-51
40. Allez M, Karmiris K, Louis E, et al. Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency, and pharmacological aspects. J Crohns Colitis 2010; 4: 355-66
41. O?Connor P, Sperl-Hillen J, Johnson P. Clinical inertia, and outpatient errors. In: Battles J, Marks ES, Lewin DI, eds. Advances in patient safety: from research to implementation. Vol 2. Rockville, MD: Agency for Healthcare Research, and Quality, 2005: 293-9
42. American College of Rheumatology. Physician Quality Reporting System (PQRS). 2011. http://www.rheumatology.org/practice/office/pqri/index.asp (accessed 24 Dec 2014
43. Koltov M, Damle NS. Health policy basics: physician quality reporting system. Ann Intern Med 2014; 161: 365-7
44. Chatterjee P, Joynt KE. Do cardiology quality measures actually improve patient outcomes?. J Am Heart Assoc 2014; 3: 1-9
45. Lamb G, Smith M, Weeks WB, et al. Publicly reported quality-of-care measures influenced Wisconsin physician groups to improve performance. Health Aff 2013; 32: 536-43
46. Choi HK, Seeger JD. Glucocorticoid use, and serum lipid levels in US adults: the third national health, and nutrition examination survey. Arthritis Care Res 2005; 53: 528-35